Vor Biopharma reported net income of -$63.03M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.85M | 1.86M | 1.87M | 1.88M | 1.92M | 1.98M | 3.35M | 3.37M | 3.39M | 3.39M | 3.41M | 3.42M | 3.43M | 3.44M | 6.24M | 6.28M | 6.68M | 9.87M | 43.01M | 54.46M | ||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 12.93M | 12.69M | 15.28M | 15.33M | 16.88M | 17.06M | 21.91M | 23.90M | 27.61M | 20.90M | 24.32M | 21.82M | 21.82M | 25.35M | 26.70M | 261.50M | 14.14M | 19.19M | 17.59M | 25.92M | ||||||
| Selling, General & AdministrativeSG&A | 5.68M | 5.61M | 7.52M | 6.46M | 7.23M | 7.66M | 8.51M | 8.28M | 7.71M | 7.23M | 8.00M | 7.21M | 6.70M | 5.96M | 6.59M | 12.79M | 13.96M | 16.77M | 17.57M | 21.93M | ||||||
| Operating ExpensesOpex | 18.60M | 18.31M | 22.80M | 21.79M | 24.10M | 24.73M | 30.42M | 32.17M | 35.32M | 28.12M | 32.33M | 29.04M | 28.51M | 31.31M | 33.29M | 274.28M | 28.11M | 35.96M | 35.16M | 47.85M | ||||||
| Operating IncomeOp. Inc | -18.60M | -18.31M | -22.80M | -21.79M | -24.10M | -24.73M | -30.42M | -32.17M | -35.32M | -28.12M | -32.33M | -29.04M | -28.51M | -31.31M | -33.29M | -274.28M | -28.11M | -35.96M | -35.16M | -47.85M | ||||||
| EBIT | -18.60M | -18.31M | -22.80M | -21.79M | -24.10M | -24.73M | -30.42M | -32.17M | -35.32M | -28.12M | -32.33M | -29.04M | -28.51M | -31.31M | -33.29M | -274.28M | -28.11M | -35.96M | -35.16M | -47.85M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.05M | 0.05M | 0.06M | 0.13M | 0.31M | 0.81M | 1.99M | 2.19M | 2.13M | 1.86M | 1.52M | 1.20M | 0.95M | 0.60M | 0.81M | 0.54M | 1.73M | 2.79M | 3.94M | 4.34M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | 4.15M | 0.00M | ||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.05M | 0.05M | 0.06M | 0.13M | 0.31M | 0.81M | 1.99M | 2.19M | 2.13M | 1.86M | 1.52M | 1.20M | 0.95M | 0.60M | 0.81M | -1299.38M | -784.58M | 1,758.82M | -184.43M | -14.96M | ||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -18.55M | -18.25M | -22.74M | -21.66M | -23.79M | -23.91M | -28.43M | -29.98M | -33.19M | -26.26M | -30.80M | -27.84M | -27.56M | -30.71M | -32.49M | -273.75M | -26.38M | -33.16M | -31.23M | -43.51M | ||||||
| Profit After TaxPAT | -18.55M | -18.25M | -22.74M | -21.66M | -23.79M | -23.50M | -28.43M | -29.98M | -33.19M | -26.26M | -30.80M | -27.84M | -27.56M | -30.71M | -32.49M | -1573.68M | -812.69M | 1,722.87M | -219.58M | -63.03M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -18.55M | -18.25M | -22.74M | -21.66M | -23.79M | -23.91M | -28.43M | -29.98M | -33.19M | -26.26M | -30.80M | -27.84M | -27.56M | -30.71M | -32.49M | -273.75M | -26.38M | -33.16M | -31.23M | -43.51M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -18.55M | -18.25M | -22.74M | -21.66M | -23.79M | -23.91M | -28.43M | -29.98M | -33.19M | -26.26M | -30.80M | -27.84M | -27.56M | -30.71M | -32.49M | -273.75M | -26.38M | -33.16M | -31.23M | -43.51M | ||||||
| Income towards Parent CompanyParent Net Inc | -18.55M | -18.25M | -22.74M | -21.66M | -23.79M | -23.91M | -28.43M | -29.98M | -33.19M | -26.26M | -30.80M | -27.84M | -27.56M | -30.71M | -32.49M | -273.75M | -26.38M | -33.16M | -31.23M | -43.51M | ||||||
| Preferred Dividend PaymentsPref Dividends | ||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -18.55M | -18.25M | -22.74M | -21.66M | -23.79M | -23.91M | -28.43M | -29.98M | -33.19M | -26.26M | -30.80M | -27.84M | -27.56M | -30.71M | -32.49M | -1573.67M | -812.68M | -33.16M | -31.23M | -43.51M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -10.05 | -10.92 | -12.19 | -11.57 | -12.52 | -12.09 | -8.58 | -8.94 | -9.82 | -7.82 | -9.06 | -8.15 | -8.05 | -8.94 | -5.21 | -251.24 | -121.63 | -3.36 | -0.73 | -0.80 | ||||||
| EPS (Diluted) | -10.05 | -10.92 | -12.19 | -11.57 | -12.52 | -12.09 | -8.58 | -8.94 | -9.82 | -7.82 | -9.06 | -8.15 | -8.05 | -8.94 | -5.21 | -251.24 | -121.63 | -3.36 | -0.73 | -0.80 | ||||||
| Shares Outstanding | 1.85M | 1.67M | 1.86M | 1.87M | 1.90M | 1.98M | 3.31M | 3.35M | 3.38M | 3.36M | 3.40M | 3.41M | 3.42M | 3.44M | 6.24M | 6.26M | 6.68M | 9.87M | 43.01M | 54.30M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.85M | 1.67M | 1.86M | 1.87M | 1.90M | 1.98M | 3.31M | 3.35M | 3.38M | 3.36M | 3.40M | 3.41M | 3.42M | 3.44M | 6.24M | 6.26M | 6.68M | 9.87M | 43.01M | 54.30M | ||||||
| EBITDA | -18.60M | -18.31M | -22.80M | -21.79M | -24.10M | -24.73M | -30.42M | -32.17M | -35.32M | -28.12M | -32.33M | -29.04M | -28.51M | -31.31M | -33.29M | -274.28M | -28.11M | -35.96M | -35.16M | -47.85M |